http://barley-benefits.com -- Another amazing testimonial by a cervical cancer survivor cured by Sante Pure Barley. To Order or Inquire: Call or Text: Philippines: 0916-3868503 (Globe) / 0947-2298138 (Smart); U.A.E: +971-507124671; Qatar: +974-55247071; http://santepurebarley.multiply.com/ http://www.facebook.com/PureBarley http://bit.ly/pfYQf0 http://bit.ly/y934jP http://bit.ly/A1nFuv http://bit.ly/zIkVuf http://bit.ly/A3cKrS http://bit.ly/waX9di http://bit.ly/zJRkVi
As breakthroughs in cancer treatments are occurring at an ever increasing rate, The Leukemia & Lymphoma Society (LLS) is shining a spotlight on the women in science who are helping to lead these advances.
Through its significant investment in cancer research – more than $1.2 billion since its founding nearly 70 years ago – LLS is committed to funding and recognizing female scientists, physicians, social workers and nurses, and encouraging young women to participate in STEM (science, technology, engineering and math) education and pursue careers in the sciences.
To view the multimedia release go to:
https://www.multivu.com/players/English/8128552-lls-women-in-science/
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
The American Association for Cancer Research (AACR) today released its annual Cancer Progress Report highlighting how federally funded research discoveries are fueling the development of new and even more effective ways to prevent, detect, diagnose, and treat cancer.
To view the multimedia release go to:
https://www.multivu.com/players/English/8385551-aacr-cancer-progress-report-2018/
On World Cancer Day, new independent evidence confirms that the increasing global trend of unhealthy and sedentary lifestyles is responsible for putting millions at an unnecessarily high risk of cancer.
New estimates released today by the World Cancer Research Fund (WCRF) global network suggest that across a range of countries, making lifestyle changes including maintaining a healthy weight, eating a healthy diet and taking regular physical activity can reduce the risk of common cancers by up to a third.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/worldcancerday/47592/
Globally renowned tennis champion and Supergoop! Co-Owner Maria Sharapova alongside Supergoop! Founder & CEO Holly Thaggard, are proud to announce the launch of Project Black Dot, a new education and activism platform with the singular mission to end the epidemic of skin cancer and improve skin health in America. Maria is the face and champion of this multidimensional platform that focuses on providing consumers with suncare education and activations year round, not just during the traditional “sun” months.
The Project Black Dot platform, which will unveil multiple initiatives throughout the coming year, will kick off today with “Project 1: Permission,” calling attention to current regulations on sunscreen in schools. This initiative will put the power into the hands of parents and schools by providing a simple, sunscreen permission slip which gives children the ability to use and apply sunscreen at school with the goal of obtaining 100,000 signed sunscreen permission slips.
To view the multimedia release go to:
http://www.multivu.com/players/English/7633051-supergoop-project-black-dot/
Now on the web, www.canceranswers123.com offers all the information about cancer in three clicks of a mouse. Medical information, clinical trials, blogs, webcasts, news in real time and video; all available at your reading leisure online at ca123.com or on a mobile app.
The latest in cancer information from the American Cancer Society is located right on the home page to help answer questions, and provide a patient support care network. Another use of the web portal is for medical practitioners who want to easily adapt an oncology specific site for use by their business or medical facility.
To view Multimedia News Release, go to http://www.multivu.com/players/English/46513-Cancer-Answers-123/
Now on the web, www.canceranswers123.com offers all the information about cancer in three clicks of a mouse. Medical information, clinical trials, blogs, webcasts, news in real time and video; all available at your reading leisure online at ca123.com or on a mobile app.
The latest in cancer information from the American Cancer Society is located right on the home page to help answer questions, and provide a patient support care network. Another use of the web portal is for medical practitioners who want to easily adapt an oncology specific site for use by their business or medical facility.
To view Multimedia News Release, go to http://www.multivu.com/players/English/46513-Cancer-Answers-123/
After fourteen years, more than $7 million raised and more than 900 wishes granted, Maggiano’s Little Italy® is proud to once again kick off its annual campaign benefiting Make-A-Wish®, a nonprofit organization that grants the wishes of children with life-threatening medical conditions. This year, Maggiano’s is tapping into Guests’ favorite weekly tradition, brunch, and inviting them to “Brunch With A Purpose,” where $1 will be donated to Make-A-Wish for every brunch entrée ordered.
To view the multimedia release go to:
https://www.multivu.com/players/English/8012052-maggianos-make-a-wish-campaign-eatadish4maw/
Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
